Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.1B 2.86B 2.64B 5.02B 338B 5.1B 34.21B 13.41B 166B 13.29B 13B 575B P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 3.09B 2.7B 2.49B 2.3B 4.37B 295B 4.45B 29.82B 11.69B 145B 11.59B 11.34B 501B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/12/2022
Compliance Officer - 31/12/2021
Investor Relations Contact - 31/07/2018
Date Insider Type Main position Quantity % Market Cap.
30/06/25Issuer sale

Chief Technology Officer

151,946 0.2028%
30/06/25Issuer sale

Head of Human Resources

305,920 0.4082%
30/06/25Issuer sale

Director

103,482 0.1381%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+81.29% 3.54B
-0.98%+2.75%+19.28%-5.07% 67.96B
-1.12%-4.82%+43.11%+214.89% 54.4B
-2.10%+0.89%-49.30%-53.47% 41.74B
-2.79%+32.50%+32.50%+32.50% 40.63B
-7.28%-7.22%+121.38%-38.35% 30.38B
-0.87%-5.13%+46.13%-29.77% 29.37B
-1.10%+1.69%+67.15%+89.97% 23.68B
+3.88%+2.16%+11.78%+201.51% 19.15B
-1.65%+16.51%+95.79%+421.83% 17.68B
Average -1.41%+0.55%+38.78%+91.53% 32.85B
Weighted average by Cap. -1.73%-0.37%+34.91%+67.36%

Financials

2023 2024
Net sales 5.45 4.77 4.39 4.07 7.72 519.93 7.85 52.62 20.63 255.32 20.45 20.01 884.39 191.59 167.6 154.56 143 271.43 18.29K 275.96 1.85K 725.57 8.98K 719.24 703.69 31.11K
Net income -325M -284M -262M -243M -461M -31.03B -468M -3.14B -1.23B -15.24B -1.22B -1.19B -52.78B -258M -226M -208M -193M -366M -24.64B -372M -2.49B -978M -12.1B -969M -948M -41.91B
Net Debt -656M -573M -529M -489M -929M -62.57B -944M -6.33B -2.48B -30.73B -2.46B -2.41B -106B -454M -397M -366M -339M -643M -43.34B -654M -4.39B -1.72B -21.28B -1.7B -1.67B -73.71B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock